Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report details a specific share repurchase transaction executed on November 2, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 688,679 Ordinary shares of 25 pence each.
- Purchase Price Range: High of 1,366.0 pence; Low of 1,340.0 pence per share.
- Treasury Shares Held: 510,989,248 shares (9.17% of total issued share capital).
- Treasury Shares (Including Unsettled): 513,427,927 shares (10.14% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,061,413,512 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 688,679 shares on November 2, 2011. Consequently, the percentage of total voting rights held in Treasury increased to 10.14% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,061,413,512) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.14% including unsettled shares).
- Review the price range paid (1,340.0 to 1,366.0 pence) against market prices on November 2, 2011.
- Note that this document does not contain financial performance data; refer to Form 20-F for full financial statements.